NO20085257L - Purinonderivater som HM74a-agonister - Google Patents
Purinonderivater som HM74a-agonisterInfo
- Publication number
- NO20085257L NO20085257L NO20085257A NO20085257A NO20085257L NO 20085257 L NO20085257 L NO 20085257L NO 20085257 A NO20085257 A NO 20085257A NO 20085257 A NO20085257 A NO 20085257A NO 20085257 L NO20085257 L NO 20085257L
- Authority
- NO
- Norway
- Prior art keywords
- purinone derivatives
- hm74a agonists
- agonists
- purinone
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81595506P | 2006-06-23 | 2006-06-23 | |
US92281807P | 2007-04-11 | 2007-04-11 | |
PCT/US2007/071891 WO2007150025A2 (fr) | 2006-06-23 | 2007-06-22 | Dérivés de purinone en tant qu'agonistes du hm74a |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20085257L true NO20085257L (no) | 2009-01-19 |
Family
ID=38721463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20085257A NO20085257L (no) | 2006-06-23 | 2008-12-16 | Purinonderivater som HM74a-agonister |
Country Status (14)
Country | Link |
---|---|
US (4) | US7511050B2 (fr) |
EP (1) | EP2044074A2 (fr) |
JP (1) | JP5584466B2 (fr) |
KR (1) | KR20090025261A (fr) |
CN (1) | CN101466714B (fr) |
AR (1) | AR061625A1 (fr) |
AU (1) | AU2007260851B2 (fr) |
BR (1) | BRPI0713619A2 (fr) |
CA (1) | CA2656039A1 (fr) |
IL (1) | IL195904A0 (fr) |
MX (1) | MX2009000170A (fr) |
NO (1) | NO20085257L (fr) |
TW (1) | TWI423977B (fr) |
WO (1) | WO2007150025A2 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0302756D0 (sv) * | 2003-10-17 | 2003-10-17 | Astrazeneca Ab | Novel Compounds |
BRPI0713619A2 (pt) * | 2006-06-23 | 2013-01-15 | Incyte Corp | composto ou prà-droga ou sal farmaceuticamente aceitÁvel do mesmo, composiÇço, e, uso do composto. |
AR061626A1 (es) * | 2006-06-23 | 2008-09-10 | Incyte Corp | Derivados de purinona como agonistas de hm74a |
EP2025674A1 (fr) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament |
WO2011107494A1 (fr) | 2010-03-03 | 2011-09-09 | Sanofi | Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation |
KR101799429B1 (ko) | 2010-05-03 | 2017-11-21 | 에스케이바이오팜 주식회사 | 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물 |
EP2582709B1 (fr) | 2010-06-18 | 2018-01-24 | Sanofi | Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
WO2013037390A1 (fr) | 2011-09-12 | 2013-03-21 | Sanofi | Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
WO2013045413A1 (fr) | 2011-09-27 | 2013-04-04 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase |
WO2018019911A1 (fr) | 2016-07-27 | 2018-02-01 | Hartis-Pharma Sarl | Combinaisons thérapeutiques pour traiter les troubles des globules rouges |
AR112457A1 (es) * | 2017-08-02 | 2019-10-30 | Lilly Co Eli | Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona |
ES2914377T3 (es) | 2017-10-27 | 2022-06-10 | Bayer Ag | Derivados novedosos de pirazolo-pirrolo-pirimidin-diona como inhibidor de P2X3 |
AU2019227607C1 (en) | 2018-02-27 | 2023-07-20 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
US11220510B2 (en) | 2018-04-09 | 2022-01-11 | Incyte Corporation | Pyrrole tricyclic compounds as A2A / A2B inhibitors |
JP7391046B2 (ja) | 2018-05-18 | 2023-12-04 | インサイト・コーポレイション | A2a/a2b阻害剤としての縮合ピリミジン誘導体 |
CN117304191A (zh) | 2018-07-05 | 2023-12-29 | 因赛特公司 | 作为a2a/a2b抑制剂的稠合吡嗪衍生物 |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1095906A (fr) * | 1977-02-14 | 1981-02-17 | Davis L. Temple, Jr. | Heterocyclopyrimidines, composes et procedes therapeutiques |
BE863525A (fr) | 1977-02-14 | 1978-07-31 | Bristol Myers Co | Heterocyclopyrimidines |
US4404380A (en) * | 1977-02-14 | 1983-09-13 | Mead Johnson & Company | Triazolopyrimidines |
AU3869789A (en) * | 1988-07-21 | 1990-02-19 | Upjohn Company, The | Pyrazolo-pyrrolo-pyrimidine-diones |
JP2980658B2 (ja) | 1989-09-14 | 1999-11-22 | 協和醗酵工業株式会社 | s―トリアゾロ〔3,4―i〕プリン誘導体 |
JPH083168A (ja) * | 1994-06-15 | 1996-01-09 | Yamasa Shoyu Co Ltd | 4−メチル−9H−イミダゾ[1,2−a]プリン−9−オン類 |
JP3204879B2 (ja) | 1995-08-04 | 2001-09-04 | オリエンタル酵母工業株式会社 | パン用酵母の包装紙 |
WO1998003411A1 (fr) | 1996-07-18 | 1998-01-29 | Montania | Bouchon avec recipient auxiliaire et procede de realisation |
DE19629378A1 (de) | 1996-07-20 | 1998-01-29 | Boehringer Ingelheim Kg | Neue Triazolopurine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
AU7966098A (en) | 1997-06-12 | 1998-12-30 | Smithkline Beecham Corporation | Hm74a receptor |
US6489331B1 (en) | 1998-07-02 | 2002-12-03 | Kyowa Hakko Kogyo Co., Ltd. | Remedies for diabetes |
WO2001047931A1 (fr) | 1999-12-24 | 2001-07-05 | Kyowa Hakko Kogyo Co., Ltd. | Derives de purine fondue |
PT1294358E (pt) | 2000-06-28 | 2004-12-31 | Smithkline Beecham Plc | Processo de moagem por via humida |
UA75625C2 (en) | 2000-12-01 | 2006-05-15 | Biogen Inc | Condensed purine derivatives as a1 adenosine receptor antagonists |
AU2002242910A1 (en) * | 2001-04-11 | 2002-10-28 | Glaxo Group Limited | Medicaments which are modulators of hm74 and/or hm74a activity |
UA80258C2 (en) | 2001-09-06 | 2007-09-10 | Biogen Inc | Methods of treating pulmonary disease |
US6902902B2 (en) * | 2001-11-27 | 2005-06-07 | Arena Pharmaceuticals, Inc. | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders |
EP1597587A2 (fr) | 2003-02-17 | 2005-11-23 | Bayer HealthCare AG | Methodes diagnostiques et therapeutiques relatives a des etats pathologiques lies au recepteur hm74a couple a la proteine g |
NZ548496A (en) * | 2004-02-14 | 2010-02-26 | Smithkline Beecham Corp | Medicaments with HM74A receptor activity for disorder of lipid metabolism |
WO2005089188A2 (fr) * | 2004-03-12 | 2005-09-29 | General Motors Corporation | Ensembles entretoise a resistance variable et articles contenant ces ensembles |
US7267695B2 (en) | 2004-06-25 | 2007-09-11 | American Prosthetic Components, Inc. | Four hole offset alignment device |
WO2006021892A2 (fr) | 2004-08-27 | 2006-03-02 | Endocube S.A.S. | Hm74 et hm74a associes a l'inflammation dans les cellules endotheliales cuboides |
KR20070070231A (ko) * | 2004-10-22 | 2007-07-03 | 스미스클라인 비참 코포레이션 | Hm74a 수용체 활성을 가지는 크산틴 유도체 |
WO2006045564A1 (fr) * | 2004-10-22 | 2006-05-04 | Smithkline Beecham Corporation | Derives de xanthine avec activite du recepteur hm74a |
GB0516462D0 (en) | 2005-08-10 | 2005-09-14 | Smithkline Beecham Corp | Novel compounds |
ATE487719T1 (de) | 2005-08-10 | 2010-11-15 | Glaxosmithkline Llc | Xanthinderivate als selektive hm74a-agonisten |
AR061626A1 (es) | 2006-06-23 | 2008-09-10 | Incyte Corp | Derivados de purinona como agonistas de hm74a |
BRPI0713619A2 (pt) | 2006-06-23 | 2013-01-15 | Incyte Corp | composto ou prà-droga ou sal farmaceuticamente aceitÁvel do mesmo, composiÇço, e, uso do composto. |
-
2007
- 2007-06-22 BR BRPI0713619-6A patent/BRPI0713619A2/pt not_active IP Right Cessation
- 2007-06-22 EP EP07798937A patent/EP2044074A2/fr not_active Withdrawn
- 2007-06-22 MX MX2009000170A patent/MX2009000170A/es active IP Right Grant
- 2007-06-22 TW TW096122480A patent/TWI423977B/zh not_active IP Right Cessation
- 2007-06-22 KR KR1020087031335A patent/KR20090025261A/ko active IP Right Grant
- 2007-06-22 CA CA002656039A patent/CA2656039A1/fr not_active Abandoned
- 2007-06-22 CN CN2007800221892A patent/CN101466714B/zh not_active Expired - Fee Related
- 2007-06-22 AR ARP070102782A patent/AR061625A1/es not_active Application Discontinuation
- 2007-06-22 US US11/766,981 patent/US7511050B2/en active Active
- 2007-06-22 JP JP2009516748A patent/JP5584466B2/ja not_active Expired - Fee Related
- 2007-06-22 AU AU2007260851A patent/AU2007260851B2/en not_active Ceased
- 2007-06-22 WO PCT/US2007/071891 patent/WO2007150025A2/fr active Application Filing
-
2008
- 2008-11-03 US US12/263,990 patent/US8039478B2/en not_active Expired - Fee Related
- 2008-12-11 IL IL195904A patent/IL195904A0/en unknown
- 2008-12-16 NO NO20085257A patent/NO20085257L/no not_active Application Discontinuation
-
2011
- 2011-10-17 US US13/275,214 patent/US8703783B2/en active Active
-
2014
- 2014-04-18 US US14/256,350 patent/US20140371216A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2009541355A (ja) | 2009-11-26 |
MX2009000170A (es) | 2009-01-23 |
US7511050B2 (en) | 2009-03-31 |
US20120035172A1 (en) | 2012-02-09 |
AR061625A1 (es) | 2008-09-10 |
WO2007150025A3 (fr) | 2008-02-07 |
US20090286774A1 (en) | 2009-11-19 |
US20080045554A1 (en) | 2008-02-21 |
EP2044074A2 (fr) | 2009-04-08 |
TWI423977B (zh) | 2014-01-21 |
US20140371216A1 (en) | 2014-12-18 |
CN101466714B (zh) | 2013-02-06 |
KR20090025261A (ko) | 2009-03-10 |
CA2656039A1 (fr) | 2007-12-27 |
JP5584466B2 (ja) | 2014-09-03 |
AU2007260851B2 (en) | 2013-01-17 |
US8039478B2 (en) | 2011-10-18 |
CN101466714A (zh) | 2009-06-24 |
AU2007260851A1 (en) | 2007-12-27 |
US8703783B2 (en) | 2014-04-22 |
TW200813064A (en) | 2008-03-16 |
IL195904A0 (en) | 2009-09-01 |
BRPI0713619A2 (pt) | 2013-01-15 |
WO2007150025A2 (fr) | 2007-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20085257L (no) | Purinonderivater som HM74a-agonister | |
NO20085099L (no) | Puritonderivativer som HM74A agonister | |
MY148429A (en) | Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof | |
NO20075298L (no) | Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists | |
NO20083462L (no) | Nye tiofenderivater som S1P1/EDG1-reseptoragonister | |
NO20083669L (no) | 4-aryl-2amino-pyrimidiner eller 4-aryl-2-aminoalkylpyrimidiner som jak-2-modulatorer og fremgangsmater for anvendelse derav | |
WO2008094992A3 (fr) | Inhibiteurs de kinase | |
NO20082793L (no) | Nye tiofenderivater | |
NO20080675L (no) | P38-Map kinaseinhibitorer og metoder for deres anvendelse | |
DE602005023197D1 (de) | -muscarinrezeptors | |
TNSN08326A1 (en) | Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments | |
TW200728307A (en) | Novel spirochromanone derivatives | |
WO2007133802A3 (fr) | Formules pharmaceutiques de pimavansérine | |
NO20093146L (no) | Amino-pyridinderivater som S1P1/EDG1-reseptoragonister | |
MA32467B1 (fr) | Derives de piperidinyle agonistes de gpcr | |
UA102251C2 (ru) | Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера | |
NO20083918L (no) | Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser | |
NO20083427L (no) | Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse | |
EA201200669A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
NO20076648L (no) | Novel thiophene derivatives | |
NO20082124L (no) | Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom | |
NO20075113L (no) | Proteinkinaseinhibitorer | |
TW200740814A (en) | Compounds | |
NO20083708L (no) | 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer | |
NO20084301L (no) | Tetrahydronaftalenderivater, fremgangsmate for deres fremstilling og anvendelse derav som anti-inflammatoriske midler |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |